Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Immunogen Inc (IMGN)

Immunogen Inc (IMGN)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
31.23 unch (unch) 02/09/24 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 31.23 unch (unch) -
Quote Overview for Fri, Feb 9th, 2024
Day Low
31.22
Day High
31.25
Open 31.24
Previous Close 31.23 31.23
Volume 48,606,800 48,606,800
Avg Vol 9,369,235 9,369,235
Stochastic %K 90.88% 90.88%
Weighted Alpha +113.70 +113.70
5-Day Change +1.97 (+6.73%) +1.97 (+6.73%)
52-Week Range 3.61 - 31.25 3.61 - 31.25
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,315,425
  • Shares Outstanding, K 266,264
  • Annual Sales, $ 108,780 K
  • Annual Income, $ -222,930 K
  • EBIT $ -80 M
  • EBITDA $ -78 M
  • 60-Month Beta 1.18
  • Price/Sales 28.51
  • Price/Cash Flow N/A
  • Price/Book 14.81
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.31
  • Most Recent Earnings $0.10 on 11/02/23
  • Next Earnings Date 03/06/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.13
  • Number of Estimates 10
  • High Estimate 0.22
  • Low Estimate 0.07
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +156.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.15 +7.14%
on 01/31/24
Period Open: 29.89
31.25 -0.06%
on 02/09/24
+1.34 (+4.48%)
since 01/09/24
3-Month
14.26 +119.08%
on 11/13/23
Period Open: 14.74
31.25 -0.06%
on 02/09/24
+16.49 (+111.87%)
since 11/09/23
52-Week
3.61 +766.30%
on 03/23/23
Period Open: 4.21
31.25 -0.06%
on 02/09/24
+27.02 (+641.81%)
since 02/09/23

Most Recent Stories

More News
Is AbbVie Stock a Buy Now?

The company is grappling with losing Humira's patent protection in 2023.

IMGN : 31.23 (unch)
CERE : 44.96 (+0.74%)
ABBV : 204.08 (+0.99%)
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why

The acquisition fills an immediate need with some extras to boot.

ABBV : 204.08 (+0.99%)
IMGN : 31.23 (unch)
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors

It's making a major acquisition to beef up a key area of its pipeline.

PFE : 26.65 (+1.33%)
ABBV : 204.08 (+0.99%)
IMGN : 31.23 (unch)
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?

The big drugmaker went on a holiday shopping spree.

AGN.AX : 0.835 (-0.60%)
ABBV : 204.08 (+0.99%)
IMGN : 31.23 (unch)
CERE : 44.96 (+0.74%)
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?

Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.

ABBV : 204.08 (+0.99%)
CERE : 44.96 (+0.74%)
IMGN : 31.23 (unch)
Is AbbVie Stock a Buy Now?

AbbVie's business could soon become more diversified.

AGN.AX : 0.835 (-0.60%)
ABBV : 204.08 (+0.99%)
IMGN : 31.23 (unch)
Why Abbvie Stock Popped Today

The company announces a major deal worth over $10 billion.

ABBV : 204.08 (+0.99%)
IMGN : 31.23 (unch)
Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio

AbbVie is spending more than $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales

$SPX : 5,983.25 (-0.50%)
$DOWI : 43,461.21 (+0.08%)
$IUXX : 21,352.08 (-1.21%)
IMGN : 31.23 (unch)
ABBV : 204.08 (+0.99%)
ImmunoGen: Q3 Earnings Snapshot

ImmunoGen: Q3 Earnings Snapshot

IMGN : 31.23 (unch)
Pioneering the Path to Cure Cancer: 2023's Biotech Innovations

VANCOUVER – Earlier this year, the US White House requested over $2.8 billion in funding from Congress for their “Cancer Moonshot” initiative, an ambitious plan to slash cancer rates in half within...

RY : 118.57 (-0.26%)
RY.TO : 169.14 (-0.05%)
ONCY : 0.7138 (-1.63%)
ONC.TO : 1.02 (-0.97%)
LLY : 881.40 (+0.88%)
IMGN : 31.23 (unch)
AZN : 74.69 (+0.63%)
MRK : 91.27 (+1.98%)
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

/PRNewswire/ -- USA News Group - Earlier this year, the US White House requested over $2.8 billion in funding from Congress for their "Cancer Moonshot"...

ONC.TO : 1.02 (-0.97%)
ONCY : 0.7138 (-1.63%)
IMGN : 31.23 (unch)
MRK : 91.27 (+1.98%)
AZN : 74.69 (+0.63%)
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 20, 2023 – USA News Group  –  Earlier this year, the US White House requested over $2.8 billion in funding from...

LLY : 881.40 (+0.88%)
RY : 118.57 (-0.26%)
RY.TO : 169.14 (-0.05%)
ONCY : 0.7138 (-1.63%)
ONC.TO : 1.02 (-0.97%)
IMGN : 31.23 (unch)
AZN : 74.69 (+0.63%)
MRK : 91.27 (+1.98%)
Markets Today: Stocks Push Higher on Strength in China and Europe

Morning Markets September E-Mini S&P 500 futures (ESU2 3) this morning are up +0.17%, and Sep Nasdaq 100 E-Mini futures (NQU2 3) are up +0.18% at a 1-week high. Stock indexes this morning are moderately...

ESH25 : 6,012.75 (+0.20%)
NQH25 : 21,431.00 (+0.05%)
COP : 98.82 (+0.90%)
DVN : 37.31 (-0.48%)
FANG : 155.23 (-0.57%)
XOM : 111.27 (+0.52%)
MRO : 28.55 (-1.28%)
SLB : 41.53 (-0.50%)
VLO : 135.06 (+0.24%)
MET : 81.21 (+0.25%)
PLTR : 90.68 (-10.53%)
ADBE : 444.42 (+0.02%)
ImmunoGen: Q2 Earnings Snapshot

ImmunoGen: Q2 Earnings Snapshot

IMGN : 31.23 (unch)
ImmunoBiochem Announces Multi-Target License and Option Agreement with ImmunoGen to Develop Next-Generation Antibody-Drug Conjugates

/PRNewswire/ - ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel...

IMGN : 31.23 (unch)
MoonLake Immunotherapeutics Makes a Moonshot on Trials

Clinical-stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive clinical trial results.

MLTX : 40.96 (-3.24%)
IMGN : 31.23 (unch)
Five Top Companies Fighting for the Treatment of Metastatic Breast Cancer

A significant medical breakthrough is needed in the fight against metastatic breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of...

LLY : 881.40 (+0.88%)
PBYI : 2.89 (-0.52%)
GILD : 111.03 (+0.98%)
IMGN : 31.23 (unch)
BCTX : 4.54 (+2.71%)
BCT.TO : 6.45 (+1.90%)
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials

ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t

IMGN : 31.23 (unch)
C : 78.54 (-1.39%)
GILD : 111.03 (+0.98%)
LEA : 97.02 (+0.64%)
PFE : 26.65 (+1.33%)
SGEN : 228.74 (-0.07%)
AZN : 74.69 (+0.63%)
Stocks Settle Mixed on Weak U.S. Economic Reports

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Monday closed down -0.205%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.59%, and the Nasdaq 100 Index ($IU XX) (QQQ ) closed...

$SPX : 5,983.25 (-0.50%)
SPY : 597.21 (-0.46%)
$DOWI : 43,461.21 (+0.08%)
DIA : 434.53 (+0.09%)
$IUXX : 21,352.08 (-1.21%)
QQQ : 519.87 (-1.18%)
INTC : 24.27 (-2.41%)
GFS : 41.52 (-2.14%)
MRVL : 97.91 (-5.68%)
QCOM : 161.10 (-2.62%)
MCHP : 60.83 (-0.39%)
MU : 95.41 (-3.47%)
Stocks Slip in Afternoon Trade

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.2%. After...

$SPX : 5,983.25 (-0.50%)
SPY : 597.21 (-0.46%)
$DOWI : 43,461.21 (+0.08%)
DIA : 434.53 (+0.09%)
$IUXX : 21,352.08 (-1.21%)
QQQ : 519.87 (-1.18%)
DVN : 37.31 (-0.48%)
MRO : 28.55 (-1.28%)
FANG : 155.23 (-0.57%)
CVX : 157.89 (+0.62%)
COP : 98.82 (+0.90%)
XOM : 111.27 (+0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

ImmunoGen Inc is a development-stage biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen's ADC technology is used in three development-stage candidates in its own pipeline, Roche's marketed product, Kadcyla...

See More

Key Turning Points

3rd Resistance Point 31.28
2nd Resistance Point 31.26
1st Resistance Point 31.25
Last Price 31.23
1st Support Level 31.22
2nd Support Level 31.20
3rd Support Level 31.19

See More

52-Week High 31.25
Last Price 31.23
Fibonacci 61.8% 20.69
Fibonacci 50% 17.43
Fibonacci 38.2% 14.17
52-Week Low 3.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements